Stock holder reports for vaccine companies producing COVID-19 jabs should be full of optimism and good news as booster requirements are implemented.
“Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus,” an AP investigation found.
Between the continual worldwide rollout of first-time shots and the boosters, Pfizer and Moderna are set to gain exponentially — and Wall Street is watching, the AP said.
“Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans,” the AP added. One reason for the boost is that booster shots won’t have research and development costs taking from the profits.
In other news, the AP said Pfizer expects its COVID mRNA shot to generate $35.5 billion in 2021, more than five times its previous highest-selling shot for pneumococcal disease.
SOURCE: AP News September 25, 2021